Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
10 Avril 2024 - 2:15PM
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”
or the “Company”), a biopharmaceutical company focused on
developing and advancing novel therapeutics for patients living
with autoimmune, inflammatory, and fibrotic diseases, today
announced that it presented at IBD Innovate: Product Development
for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA.
As part of the conference, Christophe Mellon, Chief Executive
Officer of Giiant Pharma, Inc., the Company’s research partner, and
Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral
presentation titled, “Advancing PALI-2108: Discovery to Strategy
Positioning,” which discussed the development of PALI-2108, its
differentiation and positioning in the competitive landscape as
well as a clinical pathway towards late-stage development. The
presentation is accessible on the Publications page under the
Science section of Palisade Bio’s website, www.palisadebio.com. “We
were pleased to participate with Giiant at the premier IBD
conference and provide further information on PALI-2108. We
continue to generate a growing body of data from PALI-2108 for the
treatment of UC and remain on track to launch our Phase 1 clinical
study later this year," commented Dr. Jones.
As previously announced, the development of
PALI-2108 is supported by a $500,000 research program funding
agreement with Giiant from the US Crohn’s and Colitis Foundation,
through its IBD Ventures program.
PALI-2108 is an orally administered, locally
acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug
in development for patients affected by UC.
About IBD Innovate
The Crohn's & Colitis Foundation seeks to
accelerate the discovery and development of novel products with the
potential to address the unmet needs of patients with IBD. In
pursuit of this objective, the foundation launched IBD Ventures to
directly fund product discovery and development.
IBD Innovate is the premier IBD product
development conference for therapeutics, diagnostics, devices, and
digital health.
About Palisade Bio
Palisade Bio is a biopharmaceutical company
focused on developing and advancing novel therapeutics for patients
living with autoimmune, inflammatory, and fibrotic diseases. The
Company believes that by using a targeted approach with its novel
therapeutics it will transform the treatment landscape. For more
information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking”
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding the Company’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the extent of our cash runway; our
ability to successfully develop our licensed technologies;
estimates about the size and growth potential of the markets for
our product candidates, and our ability to serve those markets,
including any potential revenue generated; future regulatory,
judicial, and legislative changes or developments in the United
States (U.S.) and foreign countries and the impact of these
changes; our ability to maintain the Nasdaq listing of our
securities; our ability to build a commercial infrastructure in the
U.S. and other markets; our ability to compete effectively in a
competitive industry; our ability to identify and qualify
manufacturers to provide API and manufacture drug product; our
ability to enter into commercial supply agreements; the success of
competing technologies that are or may become available; our
ability to attract and retain key scientific or management
personnel; the accuracy of our estimates regarding expenses, future
revenues, capital requirements and needs for additional financing;
our ability to obtain funding for our operations; our ability to
attract collaborators and strategic partnerships; and the impact of
the COVID-19 pandemic or any global event on our business, and
operations, and supply. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. These forward-looking
statements are based upon the Company’s current expectations.
Forward-looking statements involve risks and uncertainties. The
Company’s actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the Company’s ability to advance its
nonclinical and clinical programs, the uncertain and time-consuming
regulatory approval process; and the Company’s ability to secure
additional financing to fund future operations and development of
its product candidates. Additional risks and uncertainties can be
found in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, filed with the Securities and
Exchange Commission (“SEC”) on March 26, 2024. These
forward-looking statements speak only as of the date hereof and the
Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company’s
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Investor Relations Contact
JTC Team, LLCJenene Thomas
833-475-8247PALI@jtcir.com
Palisade Bio (NASDAQ:PALI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Palisade Bio (NASDAQ:PALI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024